🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the battle against drug-resistant strains of the bacteria, according to health experts.

An International Health Concern

The sexually transmitted infection are increasing worldwide, with data suggesting in excess of 82 million infections each year. Especially elevated rates are seen in Africa and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an critical and opportune development in the reality of growing infection rates, the spread of superbugs and the very limited available drugs at this time.”

Health officials are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Receive Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers hope that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This authorization signifies a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Outcomes and Global Access

Based on results released by a major medical journal, zoliflodacin eradicated more than 90% of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which combines two antibiotics. The research involved over 900 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Clinicians directly involved have shared hope. The availability of a single-dose, oral treatment like this is hailed as a "critical tool" for gonorrhoea control. This is deemed vital to reduce the burden of the illness for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.